Format

Send to

Choose Destination
Bone Marrow Transplant. 2015 Aug;50(8):1037-56. doi: 10.1038/bmt.2015.6. Epub 2015 Mar 23.

Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015.

Author information

1
Department of Haematology, Institut Catala d'Oncologia, Hospital Duran I Reynals, Barcelona, Spain.
2
Universitätsklinikum Frankfurt, Goethe-Universität, Klinik für Kinder- und Jugendmedizin, Frankfurt, Germany.
3
Paediatric Haematology Oncology, Policlinico G.B. Rossi, Verona, Italy.
4
Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
5
Clinical And Experimental Hematology Unit. Institute G. Gaslini, Genoa, Italy.
6
Department of Haematology, Leiden University Medical Center, Leiden, The Netherlands.
7
Department of Haematology-BMT, Hopital St Louis, Paris, France.
8
Children's BMT Unit, Great North Children's Hospital, Newcastle-Upon-Tyne, UK.
9
Department of Stem Cell Transplantation, University hospital Eppendorf, Hamburg, Germany.
10
Haematology and BMT Unit, Cremona, Italy.
11
Department of Haematological Medicine, King's College Hospital/King's College London, London, UK.
12
Chaim Sheva Medical Center, Tel-Hashomer, Israel.
13
Stem Cell Transplantation Unit, St Anna Kinderspital, Vienna, Austria.
14
Sezione di Ematologia, Dipartimento di Medicina Clinica e Sperimentale, Università di Perugia, Perugia, Italy.
15
Department of Haematology, H. Saint Antoine, Paris, France.
16
Anthony Nolan Research Institute, Royal Free and University College, London, UK.

Abstract

This is the sixth special report that the European Society for Blood and Marrow Transplantation regularly publishes on the current practice and indications for haematopoietic SCT for haematological diseases, solid tumours and immune disorders in Europe. Major changes have occurred in the field of haematopoietic SCT over the last years. Cord blood units as well as haploidentical donors have been increasingly used as stem cell sources for allo-SCT, thus, augmenting the possibility of finding a suitable donor for a patient. Continuous refinement of conditioning strategies has also expanded not only the number of potential indications but also has permitted consideration of older patients or those with co-morbidity for a transplant. There is accumulating evidence of the role of haematopoietic SCT in non-haematological disorders such as autoimmune diseases. On the other hand, the advent of new drugs and very effective targeted therapy has challenged the role of SCT in some instances or at least, modified its position in the treatment armamentarium of a given patient. An updated report with revised tables and operating definitions is presented.

PMID:
25798672
DOI:
10.1038/bmt.2015.6
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center